Drug intelligence / Profile preview

HV-1

Development stage: Preclinical
Lead developer: StingInn
Modality: Oncolytic Viruses → Oncolytic Therapeutics

Overview

HV-1 is a next-generation oncolytic virus developed by StingInn LLC that targets tumor cells to restore and activate Stimulator of interferon genes protein (STING) signaling. Many cancers evade the immune system by losing STING functionality; HV-1 aims to reconstitute this pathway, thereby increasing the immunogenicity of the tumor microenvironment and stimulating a robust anti-tumor immune response. It is currently in preclinical development for the treatment of various solid tumors, potentially in combination with immune checkpoint inhibitors.

Targets

STING (Stimulator of interferon genes protein)

Beyond the preview

Go deeper on HV-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HV-1.

Explore the full profile